Literature DB >> 19025518

mTORC2 is the hydrophobic motif kinase for SGK1.

Lijun Yan1, Virginie Mieulet, Richard F Lamb.   

Abstract

The activation of the AGC (protein kinase A/protein kinase G/protein kinase C)-family kinase SGK1 (serum- and glucocorticoid-induced kinase 1) by insulin via PI3K (phosphoinositide 3-kinase) signalling has been appreciated for almost 10 years. PDK1 (phosphoinositide-dependent protein kinase 1), a kinase that phosphorylates the SGK1 catalytic domain at Thr(256), is known to play a critical role in SGK1 activation. However, the identity of the protein kinase(s) responsible for phosphorylation of Ser(422), a site outside the catalytic domain (the so-called hydrophobic motif, or HM) that promotes activation of the kinase by PDK1, was unclear. In work reported in this issue of the Biochemical Journal, García-Martínez and Alessi have revealed the identity of a 'PDK2' kinase that catalyses Ser(422) phosphorylation as mTORC2 (mammalian target of rapamycin complex 2), a multiprotein kinase that phosphorylates a similar site in PKB (protein kinase B).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19025518     DOI: 10.1042/BJ20082202

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  24 in total

1.  Phospholipase D stabilizes HDM2 through an mTORC2/SGK1 pathway.

Authors:  Donggon Lyo; Limei Xu; David A Foster
Journal:  Biochem Biophys Res Commun       Date:  2010-05-08       Impact factor: 3.575

2.  Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling.

Authors:  Bruno D Fonseca; Graham H Diering; Michael A Bidinosti; Kush Dalal; Tommy Alain; Aruna D Balgi; Roberto Forestieri; Matt Nodwell; Charles V Rajadurai; Cynthia Gunaratnam; Andrew R Tee; Franck Duong; Raymond J Andersen; John Orlowski; Masayuki Numata; Nahum Sonenberg; Michel Roberge
Journal:  J Biol Chem       Date:  2012-04-02       Impact factor: 5.157

3.  Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

Authors:  Bao Hoang; Patrick Frost; Yijiang Shi; Eileen Belanger; Angelica Benavides; Gholam Pezeshkpour; Susanna Cappia; Tommasina Guglielmelli; Joseph Gera; Alan Lichtenstein
Journal:  Blood       Date:  2010-08-04       Impact factor: 22.113

Review 4.  The role of mechanistic target of rapamycin in maintenance of glomerular epithelial cells.

Authors:  Yao Yao; Ken Inoki
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-01       Impact factor: 2.894

Review 5.  mTOR kinase inhibitors as potential cancer therapeutic drugs.

Authors:  Shi-Yong Sun
Journal:  Cancer Lett       Date:  2013-06-20       Impact factor: 8.679

Review 6.  mTOR signaling in autophagy regulation in the kidney.

Authors:  Ken Inoki
Journal:  Semin Nephrol       Date:  2013-11-21       Impact factor: 5.299

Review 7.  mTORC1 senses stresses: Coupling stress to proteostasis.

Authors:  Kuo-Hui Su; Chengkai Dai
Journal:  Bioessays       Date:  2017-03-15       Impact factor: 4.345

8.  Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase α (IKKα).

Authors:  Han C Dan; Aaron Ebbs; Manolis Pasparakis; Terry Van Dyke; Daniela S Basseres; Albert S Baldwin
Journal:  J Biol Chem       Date:  2014-07-02       Impact factor: 5.157

Review 9.  Targeting SGK1 in diabetes.

Authors:  Florian Lang; Agnes Görlach; Volker Vallon
Journal:  Expert Opin Ther Targets       Date:  2009-11       Impact factor: 6.902

Review 10.  Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.

Authors:  Ewa M Kosciuczuk; Diana Saleiro; Leonidas C Platanias
Journal:  Cytokine       Date:  2016-04-16       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.